drugset / Trial / NCT02992938

Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia

NCT02992938

Phase 4 Completed 50 enrolled University of Chile
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Remifentanil is a potent opioid widely used during the administration of general anesthesia. There is a lot of evidence that suggest that the used of remifentanil is associated with the development of hyperalgesia (a reduction of nociceptive thresholds). However, the mechanism of this hyperalgesia is not fully understood. Recently, it was demonstrated that the disruption of the Cl- homeostasis could be involved. Interestingly, this was prevented in a murine model with the administration of Acetazolamide, a carbonic anhydrase inhibitor. In our clinical trial we will try to determine if the preoperative administration of acetazolamide could prevent the hyperalgesia induced by remifentanil in patients scheduled for thyroidectomy with general anesthesia.

Timeline

Start
2016-12
Primary completion
2018-09-28
Completion
2018-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetazolamide Small molecule 250 mg Oral